DRG Market Assessment reports

Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors (e.g., Johnson & Johnson…

Clarivate Epidemiology’s coverage of dry age-related macular degeneration comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy,…

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…

Treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and…

Agents for treating major depressive disorder (MDD) span multiple drug classes; while selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are…

With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space for…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the European countries (Austria, Belgium, Czech Republic…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome (IBS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IBS for…